source
- Mentari Therapeutics to go public via reverse merger with InMed, raising $290 million for migraine antibody programsMentari Therapeutics, a spinout of Paragon, announced a reverse merger with InMed Pharmaceuticals that will take the company public under the Mentari name. The deal has received board approval fro…
- BioMarin's BMN-401 fails key endpoint in ENPP1 deficiency Phase 3 trialAn experimental therapy, BMN 401, was tested in a Phase 3 study for ENPP1 deficiency, a rare disease. The drug missed one of its two co-primary endpoints, a result that regulators consider critical…